Pub Date : 2023-10-24DOI: 10.33590/emjrespir/10304494
Nicola Humphry
This symposium was held during the 2023 European Respiratory Society (ERS) International Congress in Milan, Italy. The main objective was to discuss unmet needs in the diagnosis and management of rare lung diseases, with a particular emphasis on alpha 1 antitrypsin deficiency (AATD) and idiopathic pulmonary fibrosis (IPF). Presentations focused on promising approaches to meet these needs, including the feasibility of genomic diagnosis, the development of improved biomarkers of disease progression, such as quantitative CT and novel blood biomarkers, the use of digital lung auscultation, and increased screening for AATD in vulnerable populations. The overarching message from the symposium was that advancements in technology, multidisciplinary collaboration, and partnerships between academic institutions, patient associations, and industry are crucial to the continued improvement of patient management in rare diseases, and that the education of healthcare professionals is vital to enhance the understanding and awareness of these conditions.
{"title":"Shaping the Future in Rare Lung Diseases: From Imaging to Patient Management","authors":"Nicola Humphry","doi":"10.33590/emjrespir/10304494","DOIUrl":"https://doi.org/10.33590/emjrespir/10304494","url":null,"abstract":"This symposium was held during the 2023 European Respiratory Society (ERS) International Congress in Milan, Italy. The main objective was to discuss unmet needs in the diagnosis and management of rare lung diseases, with a particular emphasis on alpha 1 antitrypsin deficiency (AATD) and idiopathic pulmonary fibrosis (IPF). Presentations focused on promising approaches to meet these needs, including the feasibility of genomic diagnosis, the development of improved biomarkers of disease progression, such as quantitative CT and novel blood biomarkers, the use of digital lung auscultation, and increased screening for AATD in vulnerable populations. The overarching message from the symposium was that advancements in technology, multidisciplinary collaboration, and partnerships between academic institutions, patient associations, and industry are crucial to the continued improvement of patient management in rare diseases, and that the education of healthcare professionals is vital to enhance the understanding and awareness of these conditions.","PeriodicalId":93286,"journal":{"name":"European medical journal. Respiratory","volume":"8 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135268156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-24DOI: 10.33590/emjrespir/10303785
Nicola Humphry
Nebuliser therapy is a relevant therapy option for respiratory diseases, yet studies have demonstrated a wide variation in nebuliser drug delivery efficiency. This study assessed the aerosol performance of 15 commercially available nebuliser systems based on a European standard, and calculated the respirable drug delivery rate (RDDR) as an objective, clinically important measure of efficiency. Findings confirmed that the efficiency of nebuliser systems differs significantly, which could potentially impact the therapeutic success of the drug delivered. The authors of the study recommend that physicians select a device with a high RDDR to ensure that patients receive clinically effective doses in a short time and thus achieve the best possible treatment effect.
{"title":"Efficiency Assessment of 15 Nebuliser Systems by the Respirable Drug Delivery Rate: A Comparable Quality Parameter","authors":"Nicola Humphry","doi":"10.33590/emjrespir/10303785","DOIUrl":"https://doi.org/10.33590/emjrespir/10303785","url":null,"abstract":"Nebuliser therapy is a relevant therapy option for respiratory diseases, yet studies have demonstrated a wide variation in nebuliser drug delivery efficiency. This study assessed the aerosol performance of 15 commercially available nebuliser systems based on a European standard, and calculated the respirable drug delivery rate (RDDR) as an objective, clinically important measure of efficiency. Findings confirmed that the efficiency of nebuliser systems differs significantly, which could potentially impact the therapeutic success of the drug delivered. The authors of the study recommend that physicians select a device with a high RDDR to ensure that patients receive clinically effective doses in a short time and thus achieve the best possible treatment effect.","PeriodicalId":93286,"journal":{"name":"European medical journal. Respiratory","volume":"58 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135273691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The authors present a case of a 77-year-old female, a former smoker with a history of chronic obstructive pulmonary disease who underwent bronchoscopy for evaluation of haemoptysis. The bronchoscopy revealed an anatomical variant of the right upper lobe bronchus with five branches instead of the usual three. This case report describes a peculiar anatomical abnormality in the right upper lobe. A review of the literature related to various variants in bronchial anatomy is presented. Conclusion: Awareness of this anatomical variation provides valuable information to clinicians, particularly thoracic surgeons, to plan surgical interventions, tailor procedures, and minimise complications.
{"title":"Five Segments of the Right Upper Lobe Bronchus on Bronchoscopic Anatomy: A Rare Case Report and Review of Literature","authors":"Priya Sharma, Deependra Kumar Rai, Manohar Kumar, Vatsal Bhushan Gupta","doi":"10.33590/emjrespir/10306996","DOIUrl":"https://doi.org/10.33590/emjrespir/10306996","url":null,"abstract":"The authors present a case of a 77-year-old female, a former smoker with a history of chronic obstructive pulmonary disease who underwent bronchoscopy for evaluation of haemoptysis. The bronchoscopy revealed an anatomical variant of the right upper lobe bronchus with five branches instead of the usual three. This case report describes a peculiar anatomical abnormality in the right upper lobe. A review of the literature related to various variants in bronchial anatomy is presented. Conclusion: Awareness of this anatomical variation provides valuable information to clinicians, particularly thoracic surgeons, to plan surgical interventions, tailor procedures, and minimise complications.","PeriodicalId":93286,"journal":{"name":"European medical journal. Respiratory","volume":"75 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135267487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-24DOI: 10.33590/emjrespir/10308211
Robin Stannard
THE FIRST European guidelines for the management of primary spontaneous pneumothorax (PSP) were presented in a symposium session delivered at the European Respiratory Society (ERS) International Congress 2023 on the 9th–13th of September in Milan, Italy. The novel guidelines covered new recommended approaches to acute pneumothorax, optimal management of persistent air leak (PAL), and analysed the evidence for the changing use of co-adjuvants in severe community-acquired pneumonia (SCAP).
{"title":"Managing Spontaneous Pneumothorax and Treating Severe Community-Acquired Pneumonia","authors":"Robin Stannard","doi":"10.33590/emjrespir/10308211","DOIUrl":"https://doi.org/10.33590/emjrespir/10308211","url":null,"abstract":"THE FIRST European guidelines for the management of primary spontaneous pneumothorax (PSP) were presented in a symposium session delivered at the European Respiratory Society (ERS) International Congress 2023 on the 9th–13th of September in Milan, Italy. The novel guidelines covered new recommended approaches to acute pneumothorax, optimal management of persistent air leak (PAL), and analysed the evidence for the changing use of co-adjuvants in severe community-acquired pneumonia (SCAP).","PeriodicalId":93286,"journal":{"name":"European medical journal. Respiratory","volume":"3 8-9","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135268177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-27DOI: 10.33590/emjrespir/20-00161
Saira Ahmad, F. Sassano, R. Tarran
Electronic nicotine delivery systems (ENDS), including electronic cigarettes (e-cigarettes), have been commercially available since the early 2000s. Since then, their use has increased both among adults and adolescents.1 E-cigarettes consist of an electric heater that aerosolises a liquid (e-liquid), which usually contains nicotine dissolved in a liquid vehicle (propylene glycol [PG] and vegetable glycerin [VG]) and chemical flavours.2 These flavours served to mask the bitter taste of nicotine, and they also facilitate the initiation and uptake of ecigarettes by attracting youth and young adults.3 In the USA alone, there are over 1,200 different vendors and over 8,000 flavors.4 E-cigarettes have undergone a series of design evolutions and are currently sold both as tank-based devices (e.g., ‘mods’, so called because of their customisability) and as cartridge-based (JUUL-type) devices, with cartridge-based ecigarette products currently being the most popular form of e-cigarette in the USA.5,6 These products are especially popular among young adults and adolescents,7 and may facilitate nicotine addiction and dependence.8
{"title":"Loose ENDs: Electronic Nicotine Delivery Systems and the FDA's Recent Enforcement Policy.","authors":"Saira Ahmad, F. Sassano, R. Tarran","doi":"10.33590/emjrespir/20-00161","DOIUrl":"https://doi.org/10.33590/emjrespir/20-00161","url":null,"abstract":"Electronic nicotine delivery systems (ENDS), including electronic cigarettes (e-cigarettes), have been commercially available since the early 2000s. Since then, their use has increased both among adults and adolescents.1 E-cigarettes consist of an electric heater that aerosolises a liquid (e-liquid), which usually contains nicotine dissolved in a liquid vehicle (propylene glycol [PG] and vegetable glycerin [VG]) and chemical flavours.2 These flavours served to mask the bitter taste of nicotine, and they also facilitate the initiation and uptake of ecigarettes by attracting youth and young adults.3 In the USA alone, there are over 1,200 different vendors and over 8,000 flavors.4 E-cigarettes have undergone a series of design evolutions and are currently sold both as tank-based devices (e.g., ‘mods’, so called because of their customisability) and as cartridge-based (JUUL-type) devices, with cartridge-based ecigarette products currently being the most popular form of e-cigarette in the USA.5,6 These products are especially popular among young adults and adolescents,7 and may facilitate nicotine addiction and dependence.8","PeriodicalId":93286,"journal":{"name":"European medical journal. Respiratory","volume":"28 1","pages":"93-96"},"PeriodicalIF":0.0,"publicationDate":"2020-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88509995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：